

Hironaga Satake

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1259045/publications.pdf>

Version: 2024-02-01

79
papers

1,290
citations

687363

13
h-index

414414

32
g-index

81
all docs

81
docs citations

81
times ranked

1690
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. <i>Gastric Cancer</i> , 2022, 25, 180-187.	5.3	10
2	Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab. <i>Case Reports in Oncology</i> , 2022, 14, 1497-1504.	0.7	3
3	Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2247.	2.4	2
4	Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial. <i>BMC Cancer</i> , 2022, 22, .	2.6	1
5	Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGS 1602. <i>Oncologist</i> , 2021, 26, 17-e47.	3.7	13
6	Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeSIS trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 65-71.	2.3	3
7	Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naïve patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 57-57.	1.6	0
8	Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Active Cancer. <i>In Vivo</i> , 2021, 35, 2747-2753.	1.3	2
9	Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).. <i>Journal of Clinical Oncology</i> , 2021, 39, 86-86.	1.6	1
10	Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 665-672.	2.3	1
11	Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. <i>PLoS ONE</i> , 2021, 16, e0246160.	2.5	7
12	Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1238-1247.	2.2	2
13	Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer: OGS 1602, survival update data.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3558-3558.	1.6	0
14	Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3529-3529.	1.6	1
15	Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. <i>BMC Cancer</i> , 2021, 21, 518.	2.6	16
16	Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases. <i>Oncologist</i> , 2021, 26, e1125-e1132.	3.7	3
17	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. <i>Investigational New Drugs</i> , 2021, 39, 1649-1655.	2.6	3
18	MO37-5 Efficacy of liquid biopsy testing for comprehensive cancer genome profiling in 88 cases. <i>Annals of Oncology</i> , 2021, 32, S322.	1.2	0

#	ARTICLE	IF	CITATIONS
19	18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12). <i>Oncology and Therapy</i> , 2021, 9, 635-645.	2.6	2
20	Dexamethasone 8â€‰%mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial. <i>Palliative Medicine Reports</i> , 2021, 2, 316-323.	0.9	2
21	A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposureâ€‰Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). <i>Clinical Colorectal Cancer</i> , 2020, 19, 13-21.e3.	2.3	17
22	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 217-223.	2.3	13
23	A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 607-618.	2.3	12
24	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). <i>Oncologist</i> , 2020, 25, e1855-e1863.	3.7	28
25	Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 1116.	2.6	2
26	Disagreement between patientâ€‰and physicianâ€‰reported outcomes on symptomatic adverse events as poor prognosis in patients treated with firstâ€‰line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. <i>Cancer Medicine</i> , 2020, 9, 9419-9430.	2.8	5
27	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 687.	2.6	9
28	Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 277-284.	2.3	4
29	<i>RAS</i> Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 898-911.	3.0	28
30	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	7.1	611
31	Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). <i>International Journal of Clinical Oncology</i> , 2020, 25, 1515-1522.	2.2	5
32	Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. <i>PLoS ONE</i> , 2020, 15, e0234314.	2.5	11
33	Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). <i>International Journal of Clinical Oncology</i> , 2020, 25, 1835-1843.	2.2	6
34	Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 972-977.	2.2	20
35	Patientâ€‰reported symptom burden as a prognostic factor in treatment with firstâ€‰line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. <i>Cancer Medicine</i> , 2020, 9, 1779-1789.	2.8	6
36	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4523-4523.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild-type colorectal cancer: OGS2016. <i>Journal of Clinical Oncology</i> , 2020, 38, 106-106.	1.6	1
38	RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2020, 38, 166-166.	1.6	0
39	Final results of multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BITS study). <i>Journal of Clinical Oncology</i> , 2020, 38, 121-121.	1.6	1
40	Quattro-II study: A multicenter randomized phase II study comparing capecitabine plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS267-TPS267.	1.6	0
41	Multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII). <i>Journal of Clinical Oncology</i> , 2020, 38, 399-399.	1.6	1
42	Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 63-68.	1.1	9
43	Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine. <i>Internal Medicine</i> , 2019, 58, 3243-3246.	0.7	1
44	The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY). <i>BMC Cancer</i> , 2019, 19, 941.	2.6	4
45	Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, vi96.	1.2	0
46	Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study. <i>Oncotarget</i> , 2019, 10, 1070-1084.	1.8	7
47	A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208). <i>Annals of Surgery</i> , 2019, 270, 230-237.	4.2	41
48	Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety. <i>International Journal of Clinical Oncology</i> , 2019, 24, 836-841.	2.2	3
49	Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06. <i>Annals of Oncology</i> , 2019, 30, vi97.	1.2	0
50	Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer. <i>Annals of Oncology</i> , 2019, 30, vi86.	1.2	0
51	Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study. <i>Breast Cancer</i> , 2019, 26, 255-259.	2.9	10
52	Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with <i>ALK</i> mutation. <i>Internal Medicine</i> , 2019, 58, 1029-1032.	0.7	19
53	Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 585-585.	1.6	7
54	Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study. <i>Journal of Clinical Oncology</i> , 2019, 37, 624-624.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BITS study).. Journal of Clinical Oncology, 2019, 37, 647-647.	1.6	2
56	The combination of the changes and the value of neutrophil-to-lymphocyte ratio is useful for prediction of response for advanced gastric cancer treated with nivolumab: A multicenter retrospective study.. Journal of Clinical Oncology, 2019, 37, 150-150.	1.6	0
57	The diagnosis and outcomes when the outpatients receiving chemotherapy visited the emergency room: A tertiary referral center retrospective study of 734 cases.. Journal of Clinical Oncology, 2019, 37, 6552-6552.	1.6	0
58	Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3560-3560.	1.6	1
59	Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial.. Journal of Clinical Oncology, 2019, 37, TPS3621-TPS3621.	1.6	1
60	Abstract 3882: Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer. , 2019, , .		0
61	Abstract 3882: Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer. , 2019, , .		0
62	Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study. International Journal of Clinical Oncology, 2018, 23, 490-496.	2.2	10
63	Expression of multiple leukemic stem cell markers is associated with poor prognosis in <i>de novo</i> acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2144-2151.	1.3	20
64	A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202). Cancer Chemotherapy and Pharmacology, 2018, 81, 461-468.	2.3	8
65	Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist, 2018, 23, 7-15.	3.7	82
66	Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports. Case Reports in Oncology, 2018, 11, 699-704.	0.7	10
67	Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to Trastuzumab (KSCC1604). European Journal of Cancer, 2018, 105, 41-49.	2.8	58
68	Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane. Cancer Chemotherapy and Pharmacology, 2018, 82, 839-845.	2.3	9
69	A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial. Cancer Medicine, 2018, 7, 4217-4227.	2.8	12
70	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e687-e697.	2.3	15
71	APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 3523-3523.	1.6	7
72	A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget, 2018, 9, 18811-18820.	1.8	27

#	ARTICLE	IF	CITATIONS
73	Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. <i>Oncotarget</i> , 2018, 9, 34520-34527.	1.8	53
74	Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 528-531.	2.0	1
75	No Correlation between KRAS Status and Advanced Pancreatic Adenocarcinoma Survival. <i>Cancer and Clinical Oncology</i> , 2017, 6, 45.	0.2	1
76	Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer. <i>Anticancer Research</i> , 2017, 37, 3703-3710.	1.1	3
77	First report of a Japanese phase I study of triplet plus bevacizumab for chemotherapy-naïve metastatic colorectal cancer (J1-TRIBE study). <i>Cancer Treatment Communications</i> , 2015, 4, 75-80.	0.4	3
78	Regorafenib-Induced Hyperammonemic Encephalopathy in Metastatic Colon Cancer. <i>Journal of Cancer Prevention & Current Research</i> , 2015, 3, .	0.1	1
79	Feasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer. <i>Journal of Cancer Therapy</i> , 2014, 05, 759-765.	0.4	1